June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Articles|July 11, 2016
How resistant biofilms affect keratitis
Watch as Ben Wucher, researcher at University of Rochester Medical Center, summarizes his research titled, "Clinical keratitis isolates of Pseudomonas aeruginosa develop resistant biofilms."
Advertisement
Watch as Ben Wucher, researcher at University of Rochester Medical Center, explains how biofilms arising from keratitis play a role in the infection cycle. Wucher summarizes his research titled, "Clinical keratitis isolates of Pseudomonas aeruginosa develop resistant biofilms."
Advertisement
Related to this article
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Alvotech files first known aflibercept 8 mg biosimilar with EMA
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
FDA approves subcutaneous Enspryng for TED
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5